Publications in collaboration with researchers from Consorci Sanitari de Terrassa (6)

2026

  1. Aspirin Discontinuation at 24–28 Weeks and Placental Biomarker Trajectories: Post Hoc Analysis of a Randomised Trial

    BJOG: An International Journal of Obstetrics and Gynaecology, Vol. 133, Núm. 3, pp. 432-441

  2. Prediction of preterm pre-eclampsia and preterm small-for-gestational-age at 24–28 weeks of gestation using ultrasound and biochemical markers in high-risk pregnancies treated with aspirin: A secondary analysis of the StopPRE trial

    International Journal of Gynecology and Obstetrics

2024

  1. Mid-trimester uterine artery Doppler for aspirin discontinuation in pregnancies at high risk for preterm pre-eclampsia: Post-hoc analysis of StopPRE trial

    BJOG: An International Journal of Obstetrics and Gynaecology, Vol. 131, Núm. 3, pp. 334-342

  2. Placental growth factor at 24–28 weeks for aspirin discontinuation in pregnancies at high risk for preterm preeclampsia: Post hoc analysis of StopPRE trial

    Acta Obstetricia et Gynecologica Scandinavica, Vol. 103, Núm. 11, pp. 2273-2280

2023

  1. Aspirin Discontinuation at 24 to 28 Weeks' Gestation in Pregnancies at High Risk of Preterm Preeclampsia: A Randomized Clinical Trial

    JAMA, Vol. 329, Núm. 7, pp. 542-550

  2. Aspirin Discontinuation at 24 to 28 Weeks’ Gestation in Pregnancies at High Risk of Preterm Preeclampsia: A Randomized Clinical Trial

    Obstetrical and Gynecological Survey